astragaloside a has been researched along with Diabetic Glomerulosclerosis in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (60.71) | 24.3611 |
| 2020's | 11 (39.29) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z; Liu, Y; Luo, P; Wu, J; Yang, W; Yang, Y | 1 |
| Fan, H; Fan, Y; Huang, L; Li, P; Liu, Q; Zhou, Y | 1 |
| Hu, Y; Hu, Z; Liu, W; Pan, C; Tang, W | 1 |
| Cao, A; Fang, J; Guo, H; Shen, Q; Su, X; Wang, H; Wang, L; Wang, Y; Yao, X; Zhu, B | 1 |
| Gao, Y; Su, X; Xue, T; Zhang, N | 1 |
| Cui, J; Gao, Y; He, J; Li, Y; Shan, X; Shi, Y; Wang, T; Xin, J; Zhu, Z | 1 |
| Fan, H; Fan, Y; Li, P; Liu, Q; Zhou, Y; Zhu, B | 1 |
| Ding, R; Fang, H; Ge, R; Huang, J; Wang, E; Wang, J; Wang, L; Wang, T; Zhai, M; Zhou, P | 1 |
| Feng, JX; Li, HY; Li, JC; Liao, XM; Meng, P; Su, YY; Wang, LN; Wang, S; Wang, YN; Zhang, YF; Zhao, SL | 1 |
| Cao, W; Jiang, J; Tao, C; Xuan, C; Zhang, Y | 1 |
| Ao, C; Chen, X; Gong, DY; Ma, YR; Zhou, XT; Zou, JJ | 1 |
| Chen, J; Fang, J; Huang, J; Wang, H; Wang, L; Wang, Y; Xing, L; Yao, X; Zhu, B | 1 |
| Cao, A; Guo, H; Peng, W; Wang, H; Wang, L; Wang, Y; Zang, Y; Zhang, X; Zhang, Y | 1 |
| Han, P; Li, S; Liu, X; Shao, M; Song, G; Sun, H; Wang, D; Wang, W; Wei, X; Wu, J; Xiong, G; Zeng, Y | 1 |
| Fang, ZH; Lin, YX; Shen, GM; Wang, TT; You, LZ; Zhao, JD | 1 |
| Lei, X; Luo, FL; Ren, JG; Zhang, BD | 1 |
| Ge, N; Han, P; Li, S; Shao, M; Song, G; Sun, H; Wang, D; Wang, W; Yi, T; Yi, W; Yu, X | 1 |
| Gao, Y; Shi, Y; Tian, N; Wang, X; Zhang, N; Zou, D | 1 |
| Lei, X; Li, Z; Ren, J; Zhang, L | 1 |
| Chen, Q; Ji, T; Ju, Y; Li, W; Ma, K; Su, Y; Wang, Z | 2 |
| Cao, X; Du, N; Gao, M; Liu, P; Sun, B; Xu, Z | 1 |
| Gao, Y; Shi, Y; Tian, N; Wang, T; Wang, X; Wu, B; Xu, J | 1 |
| Chen, J; Chen, Y; Gui, D; He, D; Huang, J; Luo, Y | 1 |
| Chen, J; Chen, Y; Gui, D; He, D; Luo, Y; Wang, N | 1 |
| Chen, D; Cheng, L; Pan, JH; Wang, ZS; Xie, XH; Xiong, F | 1 |
| Chen, LL; Guo, WW; Li, S; Li, YS; Lu, WS | 1 |
| Liang, YP; Liu, YJ; Peng, W; Wang, H; Wang, NS; Wang, YM; Yao, WG; Yao, XM; Yu, H; Zhang, XM; Zhu, BB | 1 |
3 review(s) available for astragaloside a and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease.
Topics: Diabetes Mellitus; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Humans; Kidney; Saponins; Triterpenes | 2023 |
Renal protective effects of astragaloside IV, in diabetes mellitus kidney damage animal models: A systematic review, meta-analysis.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Humans; Saponins; Triterpenes | 2020 |
[Research advances on astragaloside-IV in treatment of diabetes mellitus and its complications pharmacological effects].
Topics: Animals; Astragalus propinquus; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Saponins; Triterpenes | 2017 |
25 other study(ies) available for astragaloside a and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
The Astragaloside IV Derivative LS-102 Ameliorates Obesity-Related Nephropathy.
Topics: Animals; Benzoxazoles; Diabetic Nephropathies; Mice; Obesity; Saponins; Triazines; Triterpenes | 2022 |
Mitogen-activating protein kinase kinase kinase kinase-3, inhibited by Astragaloside IV through H3 lysine 4 monomethylation, promotes the progression of diabetic nephropathy by inducing apoptosis.
Topics: Animals; Apoptosis; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Female; Lysine; Male; Mice; Mitogens; Protein Kinases; Protein Serine-Threonine Kinases; Rats, Sprague-Dawley; Saponins; Triterpenes | 2022 |
Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease.
Topics: Animals; Chemokine CX3CL1; Diabetes Mellitus; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Fibrosis; Hyperglycemia; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Saponins; Signal Transduction; Triterpenes | 2022 |
Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Nephropathies; DNA-Binding Proteins; High Mobility Group Proteins; Kelch-Like ECH-Associated Protein 1; Mice; Mitochondria; Molecular Docking Simulation; NF-E2-Related Factor 2; Oxidative Stress; Podocytes; RNA, Small Interfering | 2023 |
Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-
Topics: Animals; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Inflammasomes; Mice; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Podocytes; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2023 |
Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Protective Agents; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Triterpenes | 2019 |
Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Caco-2 Cells; Computational Biology; Diabetic Nephropathies; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gene Regulatory Networks; Humans; Inflammation Mediators; Kidney; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Oxidative Stress; Protein Interaction Maps; Rats, Sprague-Dawley; Saponins; Triterpenes; Wnt Signaling Pathway | 2020 |
Astragaloside IV attenuates high glucose-induced EMT by inhibiting the TGF-β/Smad pathway in renal proximal tubular epithelial cells.
Topics: Animals; Apoptosis; Cadherins; Cell Line; Diabetic Nephropathies; Epithelial Cells; Epithelial-Mesenchymal Transition; Glucose; Kidney Tubules, Proximal; Nerve Tissue Proteins; Occludin; Phosphorylation; Rats; Saponins; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1; Triterpenes; Vimentin | 2020 |
Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation.
Topics: Animals; Collagen Type IV; Cytokines; Diabetic Nephropathies; Fibronectins; Fibrosis; Gene Expression Profiling; Glycation End Products, Advanced; Inflammation; Inflammation Mediators; Male; NLR Proteins; Podocytes; Protective Agents; Rats, Sprague-Dawley; Saponins; Signal Transduction; Transcription, Genetic; Triterpenes | 2020 |
Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Forkhead Box Protein O1; Gene Expression Regulation; Glucose; Glucuronidase; Klotho Proteins; Male; Mice; Mice, Inbred C57BL; Podocytes; PPAR gamma; Protective Agents; Saponins; Signal Transduction; Triterpenes | 2021 |
Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Apoptosis; Autophagy; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Male; Mice; Mice, Inbred C57BL; Podocytes; Protein Kinases; Saponins; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Triterpenes | 2017 |
Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network.
Topics: Albumins; Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Gene Regulatory Networks; Male; Mice; Mitochondria; Mitochondrial Dynamics; Saponins; Triterpenes | 2017 |
Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway.
Topics: Albuminuria; Animals; Apoptosis; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; In Situ Nick-End Labeling; Male; Mice; MicroRNAs; Podocytes; Rats; Rats, Sprague-Dawley; Receptors, Tumor Necrosis Factor; Saponins; Signal Transduction; TNF Receptor-Associated Factor 5; Transfection; Triterpenes | 2018 |
Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese Herbal; Kidney; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Protective Agents; Saponins; Triterpenes | 2018 |
Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice.
Topics: Animals; Cell Dedifferentiation; Diabetic Nephropathies; Fibrosis; Kidney; Male; Mesangial Cells; Mice; Mice, Inbred C57BL; MicroRNAs; Podocytes; Saponins; Triterpenes | 2018 |
Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats.
Topics: Animals; Apoptosis; Cells, Cultured; Diabetic Nephropathies; Male; Mice; Podocytes; Rats; Rats, Sprague-Dawley; RNA, Long Noncoding; Saponins; Signal Transduction; Streptozocin; Structure-Activity Relationship; TNF Receptor-Associated Factor 5; Triterpenes | 2018 |
Protective effects of Astragaloside IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats.
Topics: Activating Transcription Factor 4; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Down-Regulation; eIF-2 Kinase; Endoplasmic Reticulum Stress; Epithelial Cells; Male; Rats; Rats, Sprague-Dawley; Saponins; Streptozocin; Transcription Factor CHOP; Triterpenes | 2019 |
Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy.
Topics: Administration, Oral; Animals; Central Nervous System Agents; Diabetic Nephropathies; Drugs, Chinese Herbal; Fibrosis; Ginsenosides; Male; Oxidative Stress; Rats; Rats, Wistar; Saponins; Signal Transduction; Smad2 Protein; Smad3 Protein; Smad7 Protein; Transforming Growth Factor beta1; Triterpenes | 2018 |
Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-κB p65 axis.
Topics: Animals; Autophagy; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Epithelial-Mesenchymal Transition; Glucose; Kidney Function Tests; Mice; Models, Biological; Podocytes; Saponins; Sirtuin 1; Transcription Factor RelA; Treatment Outcome; Triterpenes | 2019 |
Astragaloside IV inhibits palmitate-mediated oxidative stress and fibrosis in human glomerular mesangial cells via downregulation of CD36 expression.
Topics: Animals; CD36 Antigens; Diabetic Nephropathies; Diet, High-Fat; Down-Regulation; Fatty Acids, Nonesterified; Fibrosis; Humans; Male; Mesangial Cells; Oxidative Stress; Palmitates; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Saponins; Transforming Growth Factor beta1; Triterpenes | 2019 |
Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
Topics: Animals; Cell Adhesion; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glomerular Basement Membrane; Integrin alpha3; Integrin beta1; Male; Microscopy, Electron, Transmission; Podocytes; Protective Agents; Protein Serine-Threonine Kinases; Rats, Sprague-Dawley; RNA, Messenger; Saponins; Triterpenes | 2014 |
Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats.
Topics: Activating Transcription Factor 4; Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; eIF-2 Kinase; Endoplasmic Reticulum Stress; Glucose; Heat-Shock Proteins; Male; Podocytes; Proto-Oncogene Proteins c-bcl-2; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Saponins; Signal Transduction; Transcription Factor CHOP; Triterpenes | 2014 |
Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
Topics: Analysis of Variance; Animals; Apoptosis; Blotting, Western; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Male; Podocytes; Proteinuria; Random Allocation; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reference Values; Saponins; Streptozocin; Triterpenes; Urinalysis | 2015 |
Effects of Astragaloside IV on diabetic nephropathy in rats.
Topics: Actinin; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Humans; Integrin beta1; Kidney; Male; Protein Serine-Threonine Kinases; Rats; Saponins; Triterpenes | 2015 |
Astragaloside IV prevents high glucose-induced podocyte apoptosis via downregulation of TRPC6.
Topics: Apoptosis; Calcineurin; Cell Line, Transformed; Diabetic Nephropathies; Glucose; NFATC Transcription Factors; Podocytes; Saponins; Signal Transduction; Triterpenes; TRPC Cation Channels; TRPC6 Cation Channel | 2016 |